Precision Bio rises on UK nod to test partner's genetic disorder therapy in humans

Precision Biosciences

06/03/2024 16:02

** Shares of gene editing company Precision BioSciences
 DTIL.O  rise 3.7% to $12.66 
    ** DTIL says the U.K. health regulator cleared privately
held partner iECURE's application to expand an early-mid-stage
study testing its gene therapy to treat infants with Ornithine
transcarbamylase deficiency (OTCD) 
    ** OTCD is caused by a genetic defect in a liver enzyme
responsible for breakdown and excretion of ammonia
    ** Precision has licensed its proprietary gene editing
platform to iECURE to develop the candidate, ECUR-506, which is
designed to supply a functional OTC gene and potentially correct
the disease      
    ** Including session gains, stock down 61.2% in the last 12
months 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))